Last reviewed · How we verify
Raltegravir for the first 2 weeks
At a glance
| Generic name | Raltegravir for the first 2 weeks |
|---|---|
| Sponsor | University Hospital, Geneva |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Diarrhoea
- Pain in extremity
- Neutrophil count decreased
- Syphilis
- Haemoglobin decreased
- Nasal congestion
- Aspartate aminotransferase increased
- Cough
- Rhinorrhoea
- Atrial septal defect
- Laryngomalacia
Key clinical trials
- Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection (PHASE1)
- Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF) (PHASE1)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Measurement of Plasma and Intracellular Concentrations of Raltegravir (NA)
- Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy (PHASE3)
- Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raltegravir for the first 2 weeks CI brief — competitive landscape report
- Raltegravir for the first 2 weeks updates RSS · CI watch RSS
- University Hospital, Geneva portfolio CI